<DOC>
	<DOCNO>NCT00687167</DOCNO>
	<brief_summary>The purpose study evaluate relative bioavailability ( rate extent absorption ) test formulation zonisamide capsule compare reference formulation , Zonegran® ( zonisamide ) capsule , single oral dose administer non-fasting condition .</brief_summary>
	<brief_title>Fed Bioavailability Study Zonisamide Capsules</brief_title>
	<detailed_description>The purpose study evaluate relative bioavailability ( rate extent absorption ) test formulation zonisamide capsule compare reference formulation , Zonegran® ( zonisamide ) capsule , single oral dose administer non-fasting condition . Thirty-four healthy , non-smoking , non-obese male female volunteer least 18 year age randomly assign crossover fashion receive two zonisamide dose regimen sequence 28 day washout period dose period . On morning Day 1 , 30 minute initiation standardize , high-fat breakfast , subject receive either single oral dose test formulation , zonisamide ( 1 x 100 mg capsule ) single oral dose reference formulation , Zonegran® ( 1 x 100 mg capsule ) . After 28 day washout period , morning Day 29 , 30 minute initiation standardize , high-fat breakfast , subject receive alternate regimen . Blood sample draw participant dose 72 hour post dose time sufficient adequately define pharmacokinetics zonisamide . A goal study evaluate safety tolerability regimen healthy volunteer . Subjects monitor throughout confinement portion study adverse reaction study drug and/or procedure . Blood pressure heart rate obtain prior dose schedule follow dose administration . All adverse event whether elicited query , spontaneously report observed clinic staff evaluate investigator report subject 's case report form .</detailed_description>
	<mesh_term>Zonisamide</mesh_term>
	<criteria>Screening Demographics : All volunteer select study healthy men woman 18 year age old time dose Weight range exceed ± 20 % height body frame Screening Procedures : Each volunteer complete screening process within 28 day prior Period I dose Consent document screen evaluation HIV antibody determination review , discuss , sign potential participant full implementation screen procedure Screening include general observation , physical examination , demographic , medical medication history , electrocardiogram , sit blood pressure heart rate , respiratory rate temperature The physical examination include , may limit , evaluation cardiovascular , gastrointestinal , respiratory central nervous system The screen clinical laboratory procedure include : Hematology , Clinical Chemistry , HIV antibody , Hepatitis B surface antigen , Hepatitis C antibody , Urinalysis , Urine Drug Screen , Serum Pregnancy Screen , Follicle Stimulating Hormone If female : postmenopausal 1 year surgically sterile . Volunteers recent history drug alcohol addiction abuse Volunteers presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease Volunteers whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant Volunteers demonstrate reactive screen hepatitis B surface antigen , hepatitis C antibody HIV antibody screen Volunteers demonstrate positive drug abuse screen screen study Female volunteer demonstrate positive pregnancy screen Female volunteer currently breastfeed Volunteers history allergic response ( ) zonisamide relate drug Volunteers history clinically significant allergy include drug allergy Volunteers clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) Volunteers currently use tobacco product Volunteers take drug know induce inhibit hepatic drug metabolism 28 day prior Period I dose Volunteers report donate great 150mL blood within 28 day prior Period I dose . All subject advise donate blood four week complete study Volunteers report receive investigational drug within 14 day prior Period I dose . Volunteers donate plasma ( e.g . plasmapheresis ) within 14 day prior Period I dose . All subject advise donate plasma four week complete study Volunteers report take systemic prescription medication 14 day prior Period I dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Therapeutic Equivalency</keyword>
</DOC>